Details

Autor(en) / Beteiligte

• Cusi, Maria Grazia
• Conticini, Edoardo
• Gandolfo, Claudia
• Anichini, Gabriele
• Savellini, Gianni Gori
• Valente, Serafina
• Franchi, Federico
• Scolletta, Sabino
• Percivalle, Elena
• Frediani, Bruno

Titel

Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience

Ist Teil von

• BMC infectious diseases, 2021-07, Vol.21 (1), p.1-630, Article 630

Ort / Verlag

London: BioMed Central Ltd

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Convalescent plasma (CP) and hyperimmune plasma (HP) are passive immunotherapies consisting in the infusion of plasma from recovered people into infected patients. Following pre-existing evidence in many other viral diseases, such as SARS, MERS and Ebola, CP and HP have also been proposed for the treatment of COVID-19. Nevertheless, due to the lack of large, well-designed, clinical trials, no clear-cut guidelines exist about what subtype of patient CP and HP should be administered to. Despite encouraging initial data, no strong evidence exist in support of CP and HP to treat COVID-19. In our experience, although limited due to the reduced number of patients, we found a good safety and efficacy of HP in 3 immuno-deficient subjects. Further data are needed in order to assess whether this subtype of patients may particularly benefit from passive immunization.